Adherex Announces New Chief Financial Officer.News Editors/Business Editors RESEARCH TRIANGLE PARK Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , N.C. & OTTAWA, Canada--(BUSINESS WIRE)--April 26, 2004--Adherex Technologies Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :AHX AHX American History X (movie) AHX Abyss' Highest eXperience ), a biopharmaceutical company with a broad portfolio of products under development, today announced the appointment of Mr. Jim Klein as the Company's Chief Financial Officer. "Jim will be a very strong addition to our management team," said Dr. William P. Peters, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Chairman of Adherex. "He is a seasoned executive with in-depth experience in finance and life sciences, having worked in development-stage biotechnology and 'big pharma' for a number of years. He has extensive experience in raising capital, strategic alliances, Securities and Exchange Commission reporting, investor relations Investor relations The process by which the corporation communicates with its investors. , mergers and acquisitions and treasury management." "Adherex has assembled an impressive portfolio of vascular targeting agents and is lead by an outstanding executive team with experience in the development and commercialization of pharmaceutical compounds. I look forward to working with this exciting organization," said Mr. Klein. Mr. Klein has 20 years of financial experience and was previously the Chief Executive Officer and Treasurer of DataScout Software Inc., which was recently acquired. He served as Chief Financial Officer and Treasurer of Triangle Pharmaceuticals Inc. raising more than $325 million in equity financings, including Triangle's initial public offering and listing on the NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on exchange. Prior to Triangle Mr. Klein was the International R&D Financial Controller for Burroughs Wellcome Co. Mr. Klein is a Certified Public Accountant Certified Public Accountant (CPA) An accountant who has met certain standards, including experience, age, and licensing, and passed exams in a particular state. and began his career with Price Waterhouse. About Adherex Technologies Adherex Technologies Inc. is a biopharmaceutical company with a broad portfolio of products under development. Four products are in clinical development including Exherin(TM), Adherex's lead cadherin antagonist compound, and Sodium Thiosulfate (STS (Synchronous Transport Signal) The electrical equivalent of the SONET optical signal. In SDH, the European counterpart of SONET, STS is known as STM (Synchronous Transport Module). ), a drug that protects against severe hearing loss that is often produced by platinum-based anticancer agents. Adherex's intellectual property includes broad, interlocking interlocking /in·ter·lock·ing/ (-lok´ing) closely joined, as by hooks or dovetails; locking into one another. interlocking Obstetrics A rare complication of vaginal delivery of twins; the 1st protection for cadherin-mediated adhesion and represents what the Company believes to be the world's broadest portfolio of vascular targeting and cell adhesion-inhibiting agents. The Company has offices in Research Triangle Park, North Carolina and Ottawa, Canada. For more information, please visit Adherex's website at www.adherex.com. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Certain information contained in this news release is forward-looking and is subject to unknown risks and uncertainties. The actual results, performance or achievements of the Company may differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion